KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Alnylam Pharmaceuticals (ALNY) over the last 15 years, with Q3 2025 value amounting to $3.8 million.

  • Alnylam Pharmaceuticals' Gains from Investment Securities rose 9814.34% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.0 million, marking a year-over-year increase of 5030.49%. This contributed to the annual value of $14.4 million for FY2024, which is 13849.86% up from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Gains from Investment Securities is $3.8 million, which was up 9814.34% from -$1.3 million recorded in Q2 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Gains from Investment Securities peaked at $9.8 million during Q1 2025, and registered a low of -$1.3 million during Q2 2025.
  • Moreover, its 5-year median value for Gains from Investment Securities was $2.0 million (2024), whereas its average is $2.8 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first skyrocketed by 313030.3% in 2022, then crashed by 12220.12% in 2025.
  • Alnylam Pharmaceuticals' Gains from Investment Securities (Quarter) stood at -$165000.0 in 2021, then crashed by 130.91% to -$381000.0 in 2022, then soared by 515.49% to $1.6 million in 2023, then skyrocketed by 192.36% to $4.6 million in 2024, then dropped by 16.98% to $3.8 million in 2025.
  • Its last three reported values are $3.8 million in Q3 2025, -$1.3 million for Q2 2025, and $9.8 million during Q1 2025.